Business News

Third Arc Bio to Advance Biologic Drug Development Programs on $165 Million Funding

August 01, 2024

With the Series A funding, the new biotech company will advance the development of enhanced biologics for treating solid tumors and inflammatory and immunology diseases.

AstraZeneca Completes Amolyt Pharma Acquisition and Boosts Rare Disease Pipeline

July 19, 2024

With this acquisition, AstraZeneca gets a Phase III therapeutic peptide candidate that adds to the company's rare disease pipeline.

Merck Gains Late-Stage Eye Disease Drug Candidate with EyeBio Acquisition

July 18, 2024

Merck gains a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration through its acquisition of EyeBio.

Lantheus Acquires Meilleur Technologies, PET Imaging Agent

July 15, 2024

The acquisition provides Lantheus with worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, for its Alzheimer’s disease diagnostic and treatment portfolio.

Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition

July 13, 2024

Thermo Fisher will add Olink to its Life Sciences Solutions business.

Pfizer and Evotec Partner for Drug Discovery

July 12, 2024

Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.

uniQure to Sell Its Commercial Gene Therapy Manufacturing Operations in Massachusetts to Genezen

July 10, 2024

The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services.

Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership

July 04, 2024

LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.

Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development

July 02, 2024

This collaboration aims to support and accelerate clinical development of advanced and novel technologies.

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

June 29, 2024

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.